N@N

Scott Fidel Reiterated (AMED) at Hold and Held Target at $95 on, Feb 16th, 2023

Scott Fidel of Stephens & Co., Reiterated "Amedisys, Inc." (AMED) at Hold and Held Target at $95 on, Feb 16th, 2023.

Scott has made no other calls on AMED in the last 4 months.

There are 10 other peers that have a rating on AMED. Out of the 10 peers that are also analyzing AMED, 2 agree with Scott's Rating of Hold. Following are those relevant analyst calls for the last 4 months

---

• Whit Mayo of "SVB Leerink" Maintained at Hold with Decreased Target to $85 on, Thursday, January 5th, 2023
• John Ransom of "Raymond James" Downgraded from Buy to Hold on, Thursday, October 27th, 2022

These are the ratings of the 8 analyists that currently disagree with Scott

---

• Bill Sutherland of "Benchmark" Reiterated at Strong Buy and Held Target at $120 on, Monday, February 13th, 2023
• Jonathan Yong of "Credit Suisse" Maintained at Buy with Decreased Target to $115 on, Monday, January 23rd, 2023
• Colin Rusch of "Oppenheimer" Maintained at Buy with Decreased Target to $125 on, Thursday, January 19th, 2023
• Frank Morgan of "RBC Capital" Maintained at Buy with Decreased Target to $139 on, Monday, October 31st, 2022
• David Macdonald of "Truist Securities" Maintained at Strong Buy with Decreased Target to $130 on, Friday, October 28th, 2022
• Michael Wiederhorn of "Oppenheimer" Maintained at Buy with Decreased Target to $145 on, Friday, October 28th, 2022
• Sarah James of "Barclays" Maintained at Buy with Decreased Target to $126 on, Friday, October 28th, 2022
• Justin Bowers of "Deutsche Bank" Maintained at Strong Buy with Decreased Target to $165 on, Monday, October 24th, 2022

Contributing Sources

---